13F Holdings
中文EN

RMD RESMED INC

Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 943819 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY9.0%
TTM net income YoY10.8%
TTM EPS YoY12.4%
Revenue 3-yr CAGR9.4%
Net income 3-yr CAGR20.7%

Margins

Gross margin61.1%
Operating margin33.0%
Net margin27.8%
FCF margin28.1%
EBITDA margin36.4%

Returns

ROE26.4%
ROA19.3%
ROIC (approx.)27.9%
Asset turnover0.69x

Leverage & solvency

Liabilities / assets27.6%
Debt / equity0.07x
Current ratio2.65x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.11x
Accruals ratio-2.2%
Payout ratio22.4%
Capex / revenue2.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30FY20242024-06-30FY20232023-06-30FY20222022-06-30
Income statement
Revenue$5.65B$5.15B$4.69B$4.22B$3.58B
Cost of revenue$2.20B$2.09B$2.03B$1.87B$1.55B
Gross profit$3.45B$3.05B$2.66B$2.36B$2.02B
R&D expense$378.29M$331.28M$307.52M$287.64M$253.57M
SG&A expense$1.12B$993.05M$917.14M$874.00M$737.51M
Operating income$1.89B$1.69B$1.32B$1.13B$1.00B
Pretax income$1.92B$1.68B$1.26B$1.10B$960.48M
Income tax$396.12M$276.84M$243.85M$204.11M$181.05M
Net income$1.52B$1.40B$1.02B$897.56M$779.44M
EBITDA$2.09B$1.88B$1.50B$1.30B$1.16B
EPS (basic)10.479.556.946.125.34
EPS (diluted)10.439.516.926.095.30
Dividends declared per share2.402.121.921.761.68
Weighted avg. shares (diluted)146.05M147.34M147.55M147.46M147.04M
Banking
Net interest income———-$47.38M-$22.31M
Balance sheet
Cash & equivalents$1.47B$1.21B$238.36M$227.89M$273.71M
Receivables$1.04B$939.49M$837.27M$704.91M$575.95M
Inventory$945.80M$927.71M$822.25M$998.01M$743.91M
Current assets$4.32B$3.51B$2.36B$2.37B$1.93B
PP&E, net$581.83M$550.79M$548.02M$537.86M$498.18M
Goodwill$2.91B$3.05B$2.84B$2.77B$1.94B
Intangibles$452.74M$464.86M$485.90M$552.34M$345.94M
Total assets$8.97B$8.17B$6.87B$6.75B$5.10B
Current liabilities$1.40B$1.02B$910.65M$758.53M$689.30M
Short-term debt$259.95M$9.90M$9.90M$9.90M$9.92M
Long-term debt$399.42M$658.39M$697.31M$1.43B$765.33M
Total debt$659.37M$668.29M$707.21M$1.44B$775.24M
Total liabilities$2.38B$2.21B$2.01B$2.62B$1.74B
Shareholders' equity$6.59B$5.97B$4.86B$4.13B$3.36B
Net debt-$809.87M-$541.16M$468.85M$1.21B$501.53M
Shares outstanding144.24M146.39M146.90M147.06M146.41M
Cash flow statement
Operating cash flow$1.81B$1.75B$1.40B$693.30M$351.15M
Capital expenditure$156.28M$89.86M$99.46M$119.67M$134.84M
Free cash flow$1.65B$1.66B$1.30B$573.63M$216.31M
Investing cash flow-$545.20M-$200.04M-$269.78M-$1.16B-$229.92M
Financing cash flow-$1.01B-$606.25M-$1.12B$422.87M-$128.36M
Depreciation & amortization$201.34M$198.47M$176.87M$165.16M$159.61M
Stock-based compensation$104.35M$91.66M$80.18M$71.14M$65.26M
Dividends paid$349.66M$310.88M$282.32M$258.28M$245.34M
Share buybacks$700.04M$300.02M$150.01M$0$0

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.